Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether patient‐centred outcomes for oral changes cardiovascular death compared with IV iron (very low certainty).
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).
The intervention may leads to higher number achieving target Hb or increase ≥1 g/dL (low certainty).
The intervention showed no clear difference in all‐cause mortality (low certainty).
The review found no eligible studies for this question.
The intervention led to higher all adverse events and complications; GRADE not reported.
The review found no eligible studies for this question.
The intervention showed no clear difference in recurrence of liver metastases Number of participants developing… (low certainty).
The review found no eligible studies for this question.
Losigamone probably leads to higher 50% or greater reduction in seizure frequency compared with placebo (moderate certainty).
Losigamone probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
Losigamone probably leads to higher adverse event (dizziness) compared with placebo (moderate certainty).